Neurocrine Biosciences (NBIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$155.64-1.71%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NBIX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks NBIX against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Grow revenue through increased sales of INGREZZA, CRENESSITY, and newly acquired VYKAT XR, supported by strong patient demand and market expansion.
Stated as a priority in 3 of last 3 quarters. Total revenues grew from $688 million in 2025-Q2 to $959 million in 2026-Q2, a 39% year-over-year increase, driven by INGREZZA, CRENESSITY, and VYKAT XR sales. The trajectory is delivering consistent strong revenue growth aligned with management's stated focus.
“Total revenues for the second quarter 2026 were $959 million, compared with $688 million in the prior-year period representing 39% year-over-year growth.”
“Total first-quarter 2026 net product sales were $811 million, representing 44% growth year-over-year.”
“Total fourth-quarter 2025 net product sales were $798.3 million, reflecting 29% growth year-over-year.”
Acquire Soleno Therapeutics and integrate VYKAT XR to expand rare disease portfolio and drive revenue diversification.
Stated as a priority in 3 of last 3 quarters. The acquisition of Soleno Therapeutics was announced in 2026-Q1, completed in 2026-Q2, and integrated with VYKAT XR contributing $54 million in net product sales in Q2 2026. Management is delivering on the acquisition and integration as planned.
Progress Phase 3 clinical trials for osavampator in major depressive disorder and direclidine in schizophrenia.
Stated as a priority in 3 of last 3 quarters. Management consistently highlights advancement of Phase 3 programs for osavampator in MDD and direclidine in schizophrenia. Financials show increased R&D expenses supporting these programs, indicating ongoing investment. The trajectory is delivering steady pipeline progress.
“Advancing a differentiated late-stage pipeline with Phase 3 readouts for osavampator in MDD and direclidine in schizophrenia expected in 2027.”
Maintain financial flexibility through disciplined capital allocation and a $1 billion senior secured revolving credit facility.
Stated as a priority in 2 of last 3 quarters. The company established a $1.0 billion senior secured revolving credit facility in May 2026, providing liquidity and capital flexibility. This financial move aligns with management's stated disciplined capital allocation strategy and supports ongoing operations.
Expand sales teams to support growth of INGREZZA, CRENESSITY, and launch of VYKAT XR.
Stated as a priority in 3 of last 3 quarters. GAAP SG&A expense increased from $286 million in 2025-Q2 to $440 million in 2026-Q2, reflecting investments in commercial organization and sales force expansion for INGREZZA, CRENESSITY, and VYKAT XR. The trajectory shows active delivery on this priority.
Over the trailing year it converted 1.17x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Acquisition of Soleno Therapeutics completed in May 2026, expanding Neurocrine's portfolio with VYKAT XR.”
“Announced definitive agreement to acquire Soleno Therapeutics, expected to close in Q2 2026.”
“Entered into a definitive agreement to acquire Soleno Therapeutics in April 2026.”
“Investments in osavampator Phase 3 program in major depressive disorder and direclidine Phase 3 program in schizophrenia.”
“R&D engine on track to deliver multiple first- and best-in-class medicines including Phase 3 programs for osavampator and direclidine.”
“Entered into a $1.0 billion senior secured revolving credit facility to provide additional liquidity.”
“Announced $1 billion senior secured revolving credit facility to support capital allocation.”
“Increased SG&A expense primarily reflected continued investment in our commercial organization, including expansion of INGREZZA and CRENESSITY sales teams and support for VYKAT XR.”
“Increased SG&A expense primarily reflected continued investment in our commercial organization, including expansion of INGREZZA and CRENESSITY sales teams.”
“Increased SG&A expense including incremental investment in CRENESSITY launch activities and continued investment in INGREZZA.”